TMEM239: A Drug Target / Disease Biomarker (G100288797)

Target Name: TMEM239

NCBI ID: G100288797

TMEM239

TMEM239: A Drug Target / Disease Biomarker

TMEM239 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the transmembrane protein family, which means that it is involved in the transfer of materials between the cell membrane and the cytoplasm. TMEM239 is also known as calbindin, a protein that is involved in a variety of physiological processes in the body, including cell signaling, inflammation, and stress resistance.

TMEM239 is a potential drug target because of its involvement in a number of diseases and conditions. For example, it is often expressed in various types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and lupus. In addition, TMEM239 has been implicated in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

One of the potential benefits of targeting TMEM239 as a drug target is its ability to interact with a variety of different signaling pathways. For example, TMEM239 has been shown to interact with the TGF-β pathway, which is involved in cell signaling and growth. This suggests that targeting TMEM239 with drugs that inhibit TGF-β signaling could be effective in a variety of diseases, including cancer and neurodegenerative diseases.

Another potential benefit of targeting TMEM239 is its role in the regulation of inflammation. TMEM239 has been shown to be involved in the production and regulation of pro-inflammatory cytokines, which can contribute to the development and progression of inflammatory diseases. Targeting TMEM239 with drugs that inhibit pro-inflammatory signaling could be effective in a variety of inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease.

In addition to its potential role in drug targeting, TMEM239 is also a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the regulation of inflammation and cell signaling in a variety of tissues and conditions, including cancer, autoimmune diseases, and neurodegenerative diseases. Targeting TMEM239 with drugs that specifically interact with it could be an effective way to diagnose and treat these diseases.

Overall, TMEM239 is a protein that is involved in a variety of physiological processes in the body, and it has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Transmembrane Protein 239

The "TMEM239 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM239 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets